金水宝胶囊联合异丙托溴铵气雾剂治疗慢性阻塞性肺疾病急性加重期的疗效观察

Clinical observation of Jinshuibao Capsules combined with Ipratropium Bromide Aerosol in treatment of acute exacerbation of chronic obstructive pulmonary disease

目的研究金水宝胶囊联合异丙托溴铵气雾剂治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法选取西宁市第一人民医院2015年8月—2017年8月收治的慢性阻塞性肺疾病急性加重期患者120例作为研究对象,随机将患者分为对照组和治疗组,每组各60例。对照组给予异丙托溴铵气雾剂,2揿/次,2次/d;治疗组在对照组治疗的基础上口服金水宝胶囊,3粒/次,3次/d。7 d为1个疗程,两组患者均连续治疗2个疗程。观察两组患者的临床疗效,比较治疗前后两组患者的临床症状缓解时间、肺功能指标。结果治疗后,对照组和治疗组的临床总有效率分别为80.00%、93.33%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组患者的咳嗽消失时间、喘息缓解时间和哮鸣音消失时间均显著短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、和FEV1/FVC水平均显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后治疗组肺功能指标水平显著高于对照组,两组比较差异具有统计学意义(P<0.05)。结论金水宝胶囊联合异丙托溴铵气雾剂治疗慢性阻塞性肺疾病急性加重期具有较好的临床疗效,能够显著改善患者的临床症状和肺功能,安全性较高,具有一定的临床推广应用价值。

Objective To study the clinical effect of Jinshuibao Capsules combined with Ipratropium Bromide Aerosol in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients（120 cases） with acute exacerbation of chronic obstructive pulmonary disease in Xining No. 1 People’s Hospital from August 2015 to August 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were administered with Ipratropium Bromide Aerosol, 2 presses/time, twice daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of the control group, 3 grains/time, three times daily. One course had 7 d, and patients in two groups were treated for 2 courses. After treatment, the clinical efficacies were evaluated, and the remission times of clinical symptoms, and lung function indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 93.33%, respectively, and there were differences between two groups（P 〈 0.05）. After treatment, the time of cough disappearance, the remission time of asthma, and the time of wheezing disappearance in the treatment group were significantly shorter than those in the control group, and there was difference between two groups（P 〈 0.05）. After treatment, the levels of FEV1, FVC, and FEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group（P 〈 0.05）. And the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups（P 〈 0.05）. Conclusion Jinshuibao Capsules combined with Ipratropium Bromide Aerosol has clinical curative effect in treatment of acute exacerbation of chronic obstructive pulmonary disease, can improve the clinical symptoms and lung function of patients, with good safety, which has a certain clinical application value.